Physician profile
Jonathan Buggey
NPI 1013250133
$4,248.70
in general payments reported to CMS, 2019-2025
22 companies · $489 in 2025
The $489 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,148 · 2020: $1,805 · 2021: $159 · 2022: $242 · 2023: $194 · 2024: $211 · 2025: $489.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $764 · Consulting Fee: $130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $764.18 |
| Consulting Fee | $130.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,819.55 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| United Therapeutics Corporation | $342.49 | 2024-2025 | Remodulin, Orenitram, Tyvaso |
| Astrazeneca Pharmaceuticals Lp | $162.61 | 2019-2023 | Farxiga |
| Novartis Pharmaceuticals Corporation | $156.01 | 2019 | |
| Amgen INC. | $153.36 | 2019 | |
| Gilead Sciences, INC. | $143.62 | 2020 | |
| Janssen Pharmaceuticals, INC | $62.44 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $48.22 | 2019 | |
| Portola Pharmaceuticals, LLC | $41.47 | 2019 | |
| Pfizer INC. | $40.34 | 2019 | |
| Merck Sharp & Dohme LLC | $31.34 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $29.71 | 2022-2025 | Camzyos |
| Esperion Therapeutics, INC. | $28.56 | 2020 | |
| Medtronic Vascular, INC. | $28.47 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $24.92 | 2023 | Uptravi, Opsumit |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lantheus Medical Imaging, INC. | $23.34 | 2019 | |
| Genzyme Corporation | $20.61 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.51 | 2021 | |
| Vifor Pharma, INC. | $20.49 | 2019 | |
| Cvrx, INC. | $19.20 | 2023 | Barostim Neo System |
| Daiichi Sankyo INC. | $18.52 | 2023 | Injectafer |
| Otsuka America Pharmaceutical, INC. | $12.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Buggey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.